|
1. Adjuvant gemcitabine versus Neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable Pancreatic Cancer: A randomized multicenter phase III study (NEOPAC study)
BMC Cancer Full Text
2. Low–dose decitabine versus best supportive care in elderly patients with intermediate– or high–risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Journal of Clinical Oncology
3. Randomized trial of carboplatin versus radiotherapy for stage I seminoma
Journal of Clinical Oncology
4. Duration of chemotherapy for metastatic breast cancer: A systematic review and meta–analysis of randomized clinical trials
Journal of Clinical Oncology
5. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: A meta–analysis
Breast Cancer Research and Treatment
6. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double–blind randomised phase 3 study
The Lancet Oncology - Online First
7. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab–naive or rituximab–sensitive, follicular lymphoma: A randomised phase 3 trial
The Lancet Oncology - Online First
8. Primary radiotherapy versus radical prostatectomy for high–risk prostate cancer
Cancer
9. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial
JAMA
10. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node–positive, estrogen receptor–positive breast cancer patients. Very late results of the gruppo di ricerca per la chemio–ormonoterapia adiuvante (GROCTA) 01–Trial in early breast cancer
Breast Cancer Research and Treatment
|